esg performance report report publish performance report trust commitments report also includes reporting trust priority following reporting standards progress sasb publish sustainability accounting standards board science technology sasb index illustrate report aligns affordability availability biotechnology pharmaceutical industry guidelines modern employer gri base report global reporting operating responsibly initiative gri guidelines produced gri index show environment elements gri standards covered reporting gri sasb index ungc gsk signatory un global compact ungc un global compact communication progress report contains annual communication progress esg reporting criteria find public positions range issues public independent limited assurance report policy gskcom also publish information gskcom topics including materiality assessment sustainable development goals patient group funding trade association memberships charitable grant contributions criteria working public policy groups modern slavery act statement cautionary statement document may contain forwardlooking statements forwardlooking statements give transparency rules financial conduct authority group undertakes obligation groups current expectations forecasts future events investor identify update forwardlooking statements whether result new information future events statements fact relate strictly historical current facts use words otherwise investors however consult additional disclosures group may make anticipate estimate expect intend project plan believe target documents publishes andor files us securities exchange commission words terms similar meaning connection discussion future operating sec investors wherever located take note disclosures accordingly financial performance particular include statements relating future actions prospective assurance given particular expectation met investors cautioned products product approvals future performance results current anticipated products place undue reliance forwardlooking statements forwardlooking statements sales efforts expenses outcome contingencies legal proceedings dividend subject assumptions inherent risks uncertainties many relate factors payments financial results accordance legal regulatory obligations beyond groups control precise estimate group cautions investors number including market abuse regulations uk listing rules disclosure guidance important factors including presentation could cause actual results differ materially expressed implied forwardlooking statement march trust priority trust one three longterm priorities trust build better perform value create shareholders society trust priority covers work across environmental social governance esg factors integral overall strategy approach esg external benchmarking helps us deliver sustainable performance longterm growth well detailed perform key esg ratings building trust stakeholders also reduces risk operations frequently asked investors helps us make positive social impact dow jones sustainability index djsi st pharmaceutical commitments detailed esg areas industry group make biggest difference commitments help us respond challenges opportunities industry broader society also contribute sp global sustainability award gold class many un sustainable development goals especially goal ensure access medicines index atmi ranked st atmi healthy lives promote wellbeing ages industry leader antimicrobial resistance benchmark gskcom contribution sdgs ftsegood member ftsegood index since esg governance cdp climate change b water b forests palm oil boardlevel corporate responsibility cr committee oversees timber supplier engagement leader progress commitments addressing views sustainalytics low rating expectations stakeholders gsk leadership team senior management responsible delivery trust commitments report msci aa rating regularly cr committee progress see annual vigeo eiris ranked nd pharmaceuticals sector report using science making modern technology products affordable employer address health needs available new medical innovations pricing engaged people improve health millions people achieve maintain competitive employee develop differentiated highquality year making products available engagement score needed medicines vaccines consumer responsible prices sustainable healthcare products improve health inclusion diversity business global health accelerate progress inclusion product reach diversity including aspirational targets improve global health impact rd use access strategies reach million female ethnically diverse representation infectious diseases affect children underserved people lowincome countries senior roles end recognition young people lowincome countries focusing products disability confident employer lgbt hiv malaria tb indices healthcare access health security health wellbeing development partner improve disease prevention help world better prepare future awareness access healthcare services leading company support disease outbreaks pandemic potential million people employee health wellbeing personal tackle antimicrobial resistance development responsible business reliable supply ethics values data engagement environment commit quality safety operate ethical valuesdriven use data responsibly net zero impact climate reliable supply products culture issues transparently improve patient net positive impact nature patients consumers responded swiftly scientific engagement transparently gsk esg performance report march science technology committed using science technology address health needs innovation core unique opportunity impact global health prevention treatment infectious diseases urgent public health threats growing resistance antibiotics new medical innovations malaria commitment develop differentiated highquality new tools needed reach whos malaria goals even given impact covid needed medicines vaccines consumer healthcare products improve health october recommended broader deployment rtss ase malaria vaccine reduce illness deaths malaria children use science technology discover develop innovative medicines subsaharan africa regions moderate high transmission vaccines consumer healthcare products see rd rtss first vaccine shown longterm clinical trials reduce pages annual report including treatments vaccines malaria children recommendation followed new data study covid led london school hygiene tropical medicine showed gskcom gsk annual report vaccine combined seasonal antimalarials lowers clinical episodes malaria hospital admissions severe malaria deaths around global health rd compared antimalarials alone commitment improve global health impact rd working partners make sure theres equitable longterm infectious diseases affect children young people access rtss december gavi announced decision provide lowincome countries lics focusing hiv malaria funding procurement introduction vaccine routine child tuberculosis immunisation programmes gavi eligible countries gsk committed supply million doses annually addition million doses use approach global health scienceled prioritising areas pilot programmes malawi kenya ghana secure long term supply make impact address greatest global need work product transfer also underway bharat biotech india partners ensure access innovation tackled lab become sole supplier vaccine gsk continue supply patient partnering also means share financing risk way thats adjuvant ase bharat sustainable long term two global health research centres vaccines global health hiv institute gvgh siena italy discovers effective affordable new global paediatric hiv remains global issue children disproportionately affected health vaccines pharma rd unit tres cantos spain works epidemic availability ageappropriate treatment options potential new global health medicines centres focus serious essential children around world access right care less year neglected infectious diseases low income countries lics lower middle us fda approval treatment generic dolutegravir income countries lmics including malaria tb enteric infectious diseases dispersible tablet made available key subsaharan african countries august integrated pharma vaccines rd units along facilitated publicprivate partnership clinton health access teams focusing product access capability building new single initiative unitaid two generic manufacturers mylan part viatris global health group group macleods subsequently october made regulatory submission us fda tuberculosis approval first dispersible single tablet regimen containing dolutegravir tuberculosis remains worlds leading infectious disease killer abacavir lamivudine children hiv bid provide industry leader two publicprivate research consortiums eratb simplified treatment options younger children living hiv unitetb developing novel regimens drugresistant tb unitetb newest project innovative medicines initiative imi amr accelerator aims infectious diseases accelerate improve clinical evaluation combinations existing shigella second biggest cause morbidity mortality diarrhoea novel drugs develop new treatment regimens drugresistant drug worldwide rotavirus approved vaccine widely available sensitive tb projects bring together expertise public sector industry antimicrobial resistance making current treatments shigellosis less academic partners preclinical candidates pharmaceutical less effective october first subjects vaccinated companies reduce development time significantly quadrivalent shigella vaccine candidate firsttimeinhuman clinical phase tb candidate vaccine demonstrated phase iib trial potential iii study goal develop affordable vaccine giving broad protection reduce active pulmonary tb half adults latent tb infection prevalent shigella serotypes using innovative technology licensed bill melinda gates medical research institute called gmma generalized modules membrane antigens gmma involves develop lower income countries type alliance means simple scalable production process key vaccines designed take sustainable approach global health focusing efforts use lowincome countries expertise science research partnering others ensure also partnered bill melinda gates foundation onward development longterm access key assets wellcome trust carbx start clinical development three gmma launched collaboration novartis project africa gradient based vaccines salmonella shigella effectively creating industrys support scientific research link genetic diversity patients largest vaccine pipeline protect children lowincome countries enteric response malaria tb drugs three african regions diarrheal diseases gsk esg performance report march science technology continued developing gepotidacin novel mechanism topoisomerase inhibitor tackling antimicrobial resistance uncomplicated urinary tract infections uuti gonorrhea partnership amr poses urgent threat public health modern healthcare biomedical advanced research development authority barda covid pandemic potentially exacerbated emergence amr us first time new oral antibiotic addressed infections disrupting health services like routine immunisation contributing years gepotidacin currently phase iii resistance overuse misuse antibiotics health security expertise pharmaceuticals vaccines committed rd prevent treat viral bacterial infections also promote effective commitment help world better prepare future stewardship existing new antibiotics enable access disease outbreaks pandemic potential tackle commitments recognised access medicine foundations amr antimicrobial resistance benchmark gsk industry leader third consecutive time keeping health systems resilient infectious disease threats helps protect benchmark highlighted particular diversity depth rd people well operations working help prevent pipeline particularly amrrelevant vaccines mitigate antimicrobial resistance amr strengthen pandemic rd projects relevant amr half vaccines preparedness continue see vaccination critical tool combat amr eleven taken broad approach developing covid solutions see projects target pathogens deemed critical urgent us apply science tackling virus see annual centers disease control prevention cdc see annual report report rd pipeline gskcom gsk annual report continue train healthcare professionals around world using prescribing antibiotics appropriately importance surveillance studies future pandemic preparedness continue work amr industry alliance set global limits help preempt respond next pandemic working wastewater antibiotic discharges factories progress governments stakeholders strengthen global preparedness see water means drawing weve learned covid previous outbreaks gskcom preparing future disease threats gsk annual report championing innovation promoting sustainable approaches biopharmaceutical sector public health one five companies sit pandemic preparedness partnership steering group convened uk government brought together industry international organisations experts advise g governments speed response future pandemic trinity challenge founding member announced winners inaugural competition find innovative ways better predict prevent outbreaks disease using data analytics winners included vaccineledger tracks vaccines manufacture patient using blockchain technology gsk esg performance report march affordability availability making products affordable available people around world responsible pricing access programmes partnerships pricing product reach commitment improve health millions people commitment use access strategies reach million year making products available responsible prices underserved people lower income countries products sustainable business developed markets pricing new products reflects value collaborations partners products reached deliver patients healthcare systems wider society compared available million people since set product reach target alternatives supports work meet future healthcare needs offer commitment gavi various types patient support including patient assistance programmes tiered pricing policy means reserve lowest vaccine prices coupon copay programmes reimbursement support help ensure organisations gavi international alliance improve access appropriate access medicines us provided vaccines partner gavi since founding prescribed medicines vaccines lowincome uninsured supplied million doses since helping protect underinsured medicare part patients gsk viiv healthcares millions children patient assistance programs foundation partnership includes supplying cervarix critical tool lower income engage many stakeholders support sustainable healthcare systems countries addressing cervical cancer accounts majority continued access innovative medicines example europe disease burden also supplied pneumococcal vaccine synflorix pricing zejula medicine ovarian cancer reflects value delivers seven gavieligible countries discounted price rotarix vaccine patients caregivers payers society rotavirus reaches children across gavieligible countries four lics lmics use pricing structures extend product reach see former gavi countries tiered pricing vaccines based four widelyrecognised world march also committed supply rotarix humanitarian bank gross national income country classifications high uppermiddle lower mechanism civil society organisations serving refugee emergency middle lowincome set price ceilings floors tier situations protect children vulnerable severe progressively decrease line national income classification medicines diarrhoeal disease agreement builds existing commitment lics file patents medicines enforce historic patents humanitarian mechanism pneumococcal vaccine synflorix lets companies manufacture supply generic versions gsk medicines countries longstanding supplier oral polio vaccines opv unicef supplied million doses help eradicate polio pricing access covid treatments vaccine collaborations voluntary licensing approach pricing covid treatments vaccines viiv healthcare voluntary licensing agreements generic develop recognises unprecedented scale covid huge manufacturers produce sell lowcost single fixed dose combination impact worlds population health systems striking products containing hiv medicine dolutegravir adults low balance supporting sustainability business model middle income countries similar agreements generic made series commitments relation covid vaccine manufacturers children covering countries collaborations successful including expect profit result voluntary licence agreements least million people adjuvant contribution pandemic reinvest profits made living hiv across lics lmics access generic product sales adjuvant covid pandemic phases support containing dolutegravir end least people living coronavirusrelated research longterm global pandemic preparedness hiv antiretrovirals low middleincome countries cuttingedge innovation covid therapeutics price responsibly recognise level innovation investment made supported study product donations results inline appropriate treatment alternatives since donated ten billion albendazole tablets commitments relation covid treatments vaccines see gskcom including million support efforts end lymphatic filariasis lf control intestinal worms soiltransmitted helminths sth schoolage gskcom contribution covid children according latest data benefited million people since programme began million people treated lf programme countries including million children otal excludes reach albendazole donations assessed gsk esg performance report march affordability availability continued healthcare access partnership save children aims cut number children dying preventable treatable diseases running longterm health commitment improve disease prevention awareness programmes strengthening healthcare systems finding new treatments access healthcare services million people increased emergency preparedness response capabilities passed target reached million people investing data analytics early action protocols provide efficient partnerships next year developing ambitious timely healthcare crises global health strategy gsk include setting new target training frontline health workers foster global local partnerships strengthen health systems help since partnership save children amref health africa health innovations reach patients lowincome countries care international trained frontline health workers reaching partners including save children amref viivs positive million people prevention treatment infectious diseases plus action programme want partnerships sustainable scalable maternalchild healthcare vaccination hygiene sanitation nutrition leading longterm improvements health even involvement ends collaboration gates ceo roundtable health worker support communities affected hiv leading hiv prevention viiv training programme also working bill melinda gates healthcare established hiv prevention fund support foundation pfizer jj novartis lilly train health workers six african national regional efforts end aids programme focused countries programme track train workers well capacity building advocacy efforts hiv prevention advocates establish mobile learning platform viiv healthcares positive action programme partnership amref health africa launched tb malaria viiv healthcare positive action programme launched first annual report programme ethiopia kenya improve education diagnosis track progress strategy aims explore ways treatment underserved communities disproportionately affected support peoplecentred communityled interventions help meet un pandemic later complemented specific paediatric hiv testing targets end aids component funded viiv healthcares positive action programme trains overall programme invested million reaching health workers managers strengthen health systems increase approximately people funding grants across countries access quality healthcare well improving laboratory testing diagnostics surveillance information systems supply chains strengthening healthcare systems health systems pressure covid global disparities ability overcome challenges demand fast action build resilience develop partnerships deliver healthcare needed working save children amref health africa care international meet need low middleincome countries notes community investment cash million product inkind million time million management costs million total assured dnv value gsk medicine vaccines provided us patient assistance assured dnv programs foundation million usd us pricing year change list net price change combined average net price pharmaceutical vaccines portfolio us since previous year change average list price us since previous year year list net price cagr compounded growth rate change net price discounts rebates allowances products us past years change average list price us past years product donations valued global average cost goods reported yearend results employee volunteering significantly impacted pandemic product donation included within total community investment figures reported c alculated across gsk viiv healthcare products gsk esg performance report march affordability availability continued people reached product reach target total notes people access generic dolutegravir product voluntary licensing assured dnv agreements estimated children reached synflorix gavi ' assured dnv estimated children reached rotarix gavi ' assured dnv estimated girls reached cervarix gavi ' assured dnv estimated people reached oral polio vaccine opv ' assured dnv people reached us patient assistance programs ' assured dnv total people reached doses synflorix vaccine supplied gavi million doses rotarix vaccine supplied gavi million albendazole tablets donated help eliminate lymphatic filariasis millions assured dnv albendazole tablets donated help treat intestinal worms millions assured dnv people reached health access target people accessing healthcare service worker educational session assured dnv work save children ' people accessing malaria services comic relief partnership ' healthcare workers trained partners ' people accessing healthcare worker service facility result health worker training programmes ' healthcare workers trained gates ceo roundtable programme people accessing healthcare worker service facility result gates ceo assured dnv roundtable programme people reached viiv healthcares positive action children fund pacf grants people reached viiv healthcares positive action strategy assured dnv grants people accessing treatmentcare cleft conditions smile train partnership ' hcpspharmacists trained partners se asia india dengue fever programmes ' people accessing dengue fever services partners india total people reached product reach target use access strategies reach million underserved people lower income countries products baseline chronic ongoing treatment cumulative number people access dolutegravir dtg rather annual data used sales tld tenofovir disoproxil lamivudine dolutegravir included form large majority sales worldwide around indicator include sales dtg mg singles ald abacavir lamivudine dolutegravir dtg mg dispersible tablets tafftcdtg tenofovir alafenamide emtricitabine dolutegravir dtgtc dolutegravir lamivudine product donation included within total community investment figures reported health access target improve disease prevention awareness access healthcare services million people baseline data covers period july june latest available data h data added h data proxy total data final data available april report updated reflect actual figure figure restated reflect actual data lower estimated due impact pandemic programme came end gates ceo roundtable funded five pharmaceutical companies gsk jj novartis lilly pfizer bill melinda gates foundation funder organisations equal contributor reach number calculated dividing total reach programme six gsk esg performance report march modern employer positive experience work critical attract retain motivate best people want people thrive empowered feel good keep growing engaged people disability commitment achieve maintain competitive developed threeyear plan increase disability confidence part commitment valuable pledge initiative large employee engagement score companies agree put disability agenda report progress plan get ready become two new companies important keep listening focuses recruitment retention workplace adjustments premises make sure set deliver big products services suppliers partners communications technology ambitions gsk survey one ways january part plan rolled workplace adjustments programme completed new allcompany survey shorter focused five markets including belgium canada us making available looking purpose strategy engagement culture progress employee population far programme provides specialist weve also measured key trust priorities like id safety adjustments let people perform best also check engagement remains high general industry benchmark development programmes make sure theyre accessible employees settling back levels extra boost early phases disabilities encourage let us know need better pandemic experience inclusion diversity signed international labour organizations global business disability network works promote inclusion people commitment accelerate progress inclusion disabilities workplaces around world demonstrating business diversity id including aspirational targets female benefits employing also committed become leader ethnically diverse representation senior roles organisation uk department work pensions disability confident end recognition disabilityconfident employer programme scheme encourages businesses think differently lgbt indices disability improve recruit retain develop people believe inclusive diverse business makes us disabilities leader organisations independently validated self successful making peoples potential also assessment support disabled employees global makes us better responding patients consumers different needs company strive apply learnings disability confidence scheme across whole organisation committed achieving equity employment practices order create inclusive workplace support people undertake recognised disability matters awards north annual inclusion diversity training programme facilitate conversations america honouree disability workforce category commitment bring together employees levels discuss learn experiences people disabilities inclusion gsk leadership programmes ensure gender leaders strong focus creating inclusive workplace launched global gsk allyship campaign encourage people take aspiration women hold vp svp roles end action support inclusive workplace overall percentage women positions directorlevel continues rise women held roles vp members gsk leadership team glt lead four diversity councils full breakdown women management data covering disability gender lgbt race ethnicity councils level available data tables comprise senior leaders partner employees members employee resource groups work priorities dimension early ftse women leaders ranking showed top diversity ftse organisations based proportion women board leadership positions backing diversity recruitment continued accelerating difference womens programme supports changed recruitment policy require diverse development women individual group coaching address shortlists senior vacancies whether recruited internally externally development gaps build strengths since women includes shortlists executive search partners taken part research shows participants programme reviewed recruitment process worked external higher levels engagement likely stay us partner ensure understand implement best practices women nominate programme making making good progress implementing recommendations include accessible enabling us develop broader pool participants enhanced training recruiting managers selection process starts published fifth annual uk gender pay gap report gender review job postings channels make sure reaching pay gap permanent ukbased gsk employees mean attracting diverse candidates outperforming national average conduct countrybased reviews ensure markets clear guidance tools support ensure pay equity unexplainable differences detected address compensation processes gskcom uk gender pay gap report gsk esg performance report march modern employer continued lgbt continuously monitor impact covid employees goal recognised global lgbt indices lgbt rights analyse key trends additional resources may need allocated group stonewall recognised gsk top global employers list list closely follow public health guidance local legislation industry best paused due pandemic resume mid practices provide guidance protective measures including personal designated best place work lgbtq equality human protective equipment covid testing site infrastructure changes rights campaign foundations corporate equality index also setting capacity limits sites areas site founding member proud science alliance collective lgbtq canteens cafes meeting rooms laboratories implementing social networks work together raise bar lgbtq inclusion across distancing measures deskbooking systems health life sciences sector committed work partners offer covid vaccinations minimal cost employees eligible dependents absence race ethnicity public health vaccination programmes committed equality representation means constantly strive ensure workforce reflects communities supporting mental health wellbeing work hire believe mental health wellbeing important physical health countries meet criteria data confidentiality anonymity wellbeing encourage everyone open ask help including proportion employee data reported size relevant support need populations disclose race ethnicity people level mental health training available employees managers aspirational targets ethnically diverse leaders us uk completed since first launched early successfully piloted continued meet data criteria aspiration least new wellbeing programme mywellbeing focusing resilience strategies ethnically diverse leaders roles vp us least energy management focus mental health wellbeing uk end expecting see progress across planning global implementation groups time uk well specifically focus increasing continue ensure confidential support available global percentage black vp leaders year year us well employee assistance programme provide preventive health services specifically focus increasing percentage black african american employees well dependants awardwinning hispanic latinx vp leaders yearonyear programme partnership prevention december ethnically diverse leaders vp keeping people safe roles us percentages black african american hispanic latinx vp leaders care deeply health safety employees complementary us also increased respectively workers everyone visits sites ambition everyone uk ethnically diverse leaders roles vp goes home safe run health safety training people tailored percentage black vp leaders whether working office field lab manufacturing uk remains continue focus efforts site training covers identify take measures reduce workplace making progress area levels leadership increased risks proportion ethnically diverse people see data broken employee fatalities fatalities involving contractors ethnicity group leadership level reportable injury illness rate remained per hours support progress area continuing focus equal worked global safety programme key initiatives focusing employment opportunity including limited expectation diverse safety continuing candidate pools key roles also set aspirations ethnically diverse employees drive company business run driver candidates uk us early talent programmes apprentices safety programme combining online learning practical road safety graduate trainees strengthen future pipeline also launched activities around drivers countries currently accelerating difference ethnic diversity programme supports enrolled development ethnically diverse employees building strengths addressing development gaps individual group coaching developing people sponsorship support achieving full potential want people keep growing careers everyone gsk publish gsks ethnicity pay gap data uk chance discuss agree development plan manager everyone also access learning resources internal health wellbeing development development portal keep growing campus portal offers development commitment leading company support courses videos articles variety topics including decision making employee health wellbeing personal development building change capability coaching influencing others health wellbeing leadership business courses completed responding covid advance development global leadership team continued oversee covid develop leaders stages careers training programme response includes health wellbeing engagement first line leaders designed around four manager accountabilities employees locations whether theyre working site research motivate focus care develop helps us embed culture manufacturing facilities home customerfacing weve continued clear expect managers measure impact efforts develop policies ensure safe workplace protect programme one manager feedback tool survey employees irrespective role location people give managers direct feedback committed recruiting developing people start careers currently people graduate mba programmes globally apprenticeships countries gsk esg performance report march modern employer continued notes eennggaaggeemmeenntt employee survey engagement score assured dnv employee survey response rate ggeennddeerr ddiivveerrssiittyy percentage women employees svpvp level director level manager level total women management assured dnv percentage women board hheeaalltthh aanndd ssaaffeettyy number fatalities employees complementary workers gsk direct assured dnv supervision fatalities contractors gsk direct supervision assured dnv reportable injuries lost time assured dnv reportable illnesses lost time assured dnv lost time reportable injury rate per hours worked assured dnv lost time reportable illness rate per hours worked assured dnv reportable injuries without lost time assured dnv reportable illnesses without lost time assured dnv reportable injury rate per hours worked assured dnv reportable illness rate per hours worked assured dnv reportable injury illness rate per hours worked assured dnv hours worked million assured dnv talent leadership development number graduates recruited future leaders programme number postgraduates recruited esprit programme number apprentices recruited assured dnv employee turnover overall turnover assured dnv turnover voluntary leavers permanent leavers male female overall turnover male overall turnover female people calculated number permanent employees voluntarily left gsk divided average permanent headcount c alculated number permanent employees left gsk reason within period male female divided total number permanent leavers left reason within period gsk esg performance report march modern employer continued svpvp director manager employees us ethnic diversity american indian alaska native asian black african american hispanic latinx native hawaiian pacific islander two races ethnically diverse total white total uukk eetthhnniicc ddiivveerrssiittyy asian black mixed ethnically diverse total white total data represents responded identify race ethnicity category us employees actively respond identify race ethnicity category indicated prefer say uk actively respond indicated prefer say due rounding sum data may marginally different totals us uk ethnically diverse total percentage data assured dnv subcategories assured due confidentiality constraints insufficient data report fewer three employees gsk esg performance report march operating responsibly operating responsible business means transparent science data delivering reliable supply highquality products protecting valuesdriven culture issues responded swiftly transparently reliable supply managers people selected higherrisk roles get extra training antibribery corruption abac helps identify mitigate abac commit quality safety reliable supply products risk especially thirdparty relationships recognise report manage patients consumers conflicts interest employees contract workers priority us make sure theres highquality reliable supply completed training products patients consumers continued high importance throughout pandemic put increased strain global reporting investigating concerns supply chains anyone inside outside gsk raise concerns speak independent third party integrity lines confidentially anonymously without fear quality management systems allow continuous improvement helping us retaliation keep high standards product quality safety make sure comply relevant regulations including good manufacturing practice take every concern seriously review every report see whether good laboratory practice good pharmacovigilance practice good clinical need investigate formally investigations show employee practice external regulatory inspections breached policies take action manufacturing sites local operating companies many changed way report disciplinary data expanded conducted virtually pandemic respond inspection scope include cases initiated previous years findings matter minor employees concerns raised additional employees ran quality audits suppliers audits clinical trials concerns raised prior years open cases disciplined run behalf gsk assess quality safety find employees initially concerns raised previous years areas improve create improvement plans track progress increase primarily driven late completion mandatory training find significant issues stay unresolved might choose suspend either left voluntarily dismissed received third party stop working written warning cases took action short written warning end cases awaiting investigation disciplinary decision pharmacovigilance information see pages medicines vaccines consumer products risks well benefits pharmacovigilance enhances patient care safety around using medicines human rights vaccines supports public health programmes reliable balanced respect human rights throughout global operations continue information overall benefits risks products well deepen understanding human rights impacts associated established rigorous worldwide system monitor review safety activities products throughout clinical development regulatory approval year undertook independent assessment approach keep high standards safety medical governance make sure managing human rights help us better understand continue partners improve manage priority human rights areas access healthcare research practices patient safety environment health safety privacy set stop manufacture distribution counterfeit gsk products assessment showed good understanding human rights working international law enforcement also play active role impacts reviewing addressing findings year associations promote harmonized approaches procedures clinical come members pharmaceutical supply chain initiatives human development safety evaluation drugs implement key regulations rights labour subcommittee contributed number projects well pressing improvements legislation enforcement including online learning build suppliers capability address human rights counterfeit goods engagement carnaba wax producers brazil gsks support prosecutions manufacturers counterfeit gsk products resulted many custodial sentences million fines working third parties third parties act direct impact us meeting priorities ethics values important manage relationships well including way commitment operate ethical valuesdriven culture choose contract monitor issues responded swiftly transparently thirdparty oversight tpo programme evaluates mitigates risks culture guides people behave ethical way right thing introduced engaging thirdparties provide goods services gsk act concerns important people live complete assessments portion third parties may present expect suppliers greater potential risk example interactions government officials annual transfers value certain predefined limits supporting gsk people right thing ran assessments higher risk third parties committed operating responsibly continue expect across risk areas identifying highrisk one everyone works us behalf conducts right areas third parties goods services providers way line code conduct protects business helps contract manufacturers external suppliers distributors create workplace thrive wholesalers everyone gsk complete training company expects evaluating tpo programme simplify upfront assessment employees renamed training working gsk improved broaden focus risk management throughout thirdparty relationship content focus risk compliance well diversity creating using user feedback findings ongoing monitoring inclusive workplace employees contract workers completed training gsk esg performance report march operating responsibly continued give extra support biggest suppliers volume critical rd oversight boards new advisory panel oversees rd visit sites person virtually help suppliers better understand controls manage use reuse data respond bioethical control risks use tools assess suppliers manage ehs questions research activities makes sure follow regulations risks including ecovadis desktop assessments set ehs requirements meet ethical obligations suppliers tell fall short review ehs performance also partner transcelerate consortiums effort create part internal ehs governance oversight harmonised approach exchanging data internationally across continued work suppliers reduce environment health pharmaceutical industry safety ehs risks ran audits ehs ethics compared making clinical trials transparent help suppliers improve safety overall capability focusing mainly part commitment data transparency clinical studies active pharmaceutical ingredients api manufacturers contract published clinical study reports summaries results manufacturing suppliers also trained suppliers ehs topics revised listed studies data sharing via wwwvivliorg ehs contractual obligations tracked management actions wwwclinicalstudydatarequestcom completed patient scientific engagement data engagement ran patient panels disease areas including cancer rheumatoid commitment use data responsibly transparently arthritis hepatitis b panels give us insights advice well improve patient scientific engagement building trusting longterm relationships patients carers help us living commitment means develop medicines meet patients needs also created process get managing data carefully patient feedback design clinical trials want clinical trials representative accessible possible sharing results clinical studies reflecting patient populations disease including age race ethnicity integrating patient insights product development sex gender past five years endeavoured improve patient diversity clinical trials implementing training support giving healthcare professionals relevant accurate information personnel investigator sites including awareness training conducting need clinical trials underserved communities built work formed global demographics diversity team coordinate learning using data responsibly epidemiology burden disease health equity relate simplified privacy notices made easier access age sex gender race ethnicity apply lessons portal websites planning trials privacy part mandatory working gsk annual training read approach engaging hcps see code hcp people complete means understand everyone gsk engagement responsible handling personal information right way privacy team gskcom clinical trial diversity patient engagement engaging hcps gets certification international association privacy professionals along ongoing privacy education needed maintain notes ethical conduct employees disciplined policy violations breakdown types policy violation behaviour workplace assured dnv mandatory training completion assured dnv good manufacturing distribution practices assured dnv marketing promotional activities assured dnv expenses assured dnv assured dnv employees dismissed agreed leave company voluntarily documented warnings n changed way collect disciplinary data improve clarity example removing number categories deem behavioural policy violation n updated reporting methodology previous years reported accusations raised subsequent disciplinary actions reporting period data includes employees disciplined policy violations reporting year cases closed expanded scope includes accusations previous years employee disciplined enable comparison prior year data updated using new reporting methodology result figures category saw changes prior years increases driven disciplinary action prior year open cases category representative disciplinary action late completion mandatory training triggered due date markets following eight day grace period permitted employees must subsequently complete training overall completion rates published see supporting gsk people right thing disciplinary actions related late completion mandatory training assigned due subsequently completed policy violation types fit categories specified gsk esg performance report march operating responsibly continued notes political engagement spend federal lobbying activities data registered us federal lobbying register includes cost operating office washington dc cost travel consulting cost representing interests eu institutions data published eu transparency register political action committee contributions us employees state federal breakdown pac spend candidates available online clinical trial management pharmacovigiliance transparency clinical trial audits trials conducted rd parties behalf number fda sponsor inspections related clinical trial management pharmacovigilance resulted voluntary action indicated vai number fda sponsor inspections related clinical trial management pharmacovigilance resulted official action indicated oai publicly available trial result summaries assured dnv studies clinical study reports posted register trials listed patient level data available request research teams approved access gsk trial data quality inspections audits audits rd parties quality processes assured dnv regulatory inspections regulatory inspections pharmaceutical business regulatory inspections vaccines business regulatory inspections consumer healthcare business total assured dnv fda product recalls business class iiiiii pharmaceuticals nr assured dnv vaccines nr assured dnv consumer healthcare nr assured dnv number fda enforcement actions taken response violations current good manufacturing practices cgmp pharmaceuticals nr assured dnv vaccines nr assured dnv consumer healthcare nr assured dnv includes latest available figures previous year figures reporting year published march publication document figure cumulative data corrected original datapoint misstated due duplication data one part business additional supplier audits identified previously reported comprises one class ii one class iii recall representing total doses vaccines manufactured globally c lass iii recall represents total consumer healthcare products produced globally comprises five class ii recalls one class iii representing total consumer healthcare product batches manufactured gsk esg performance report march environment want play part protecting restoring planets health protect improve peoples health achieve set specific targets across direct operations supply value chain chains portfolio goals apply principally new gsks business latest available data scope emissions reduced portfolio consumer healthcare business contributes towards goals reflecting evolution product portfolio reductions business travel delivery targets whilst part gsk capital markets commuting result pandemic day february consumer healthcare announced new targets new business published website metered dose inhalers asthma copd account carbon footprint propellant potent greenhouse gas gskcom environment targets started rd programme find lowerimpact propellant could climate reduce emissions inhalers goal net zero impact climate across full value november joined nine global pharmaceutical companies launch chain energize programme first collaboration kind use scale single industrys global supply chain drive greater use renewable science based targets initiative accredited carbon targets electricity power purchase agreements make renewable align c pathway electricity accessible thousands companies part pharmaceutical climate targets supply chains net zero emissions across operations scope also partnered manufacture help us proactively engage suppliers measure manage emissions reductions renewable electricity scope supply chain net zero emissions across full value chain scope recognise suppliers efforts reduce environmental impact annual supplier environmental sustainability awards publish winning value chain carbon footprint made case studies gskcom scope emissions operations gskcom supplier awards scope emissions suppliers logistics collaborating across sector scope emissions people using products mostly metered september pharmaceutical medical technology sector reached dose inhalers race zero breakthrough target major companies revenue committing net zero carbon emissions november part scope emissions un global climate change conference cop glasgow championed need action climate nature protect health announced operations energize programme reduce emissions across sectors shared supply reduced scope carbon emissions compared chain also joined health systems task force sustainable primarily increased use renewable electricity markets initiative drive collective action digital healthcare supply chains patient care pathways accelerate shift net zero member committed source renewable electricity reached renewable electricity increase climaterelated financial disclosures since sites countries including uk belgium see pages annual report disclosure climate risk spain source renewable electricity resilience according task force climaterelated financial disclosures september announced million investment uk us tcfd framework manufacturing sites secure renewable power generation includes new wind turbines year power purchase agreement supply solar nature electricity irvine facility scotland solar energy oak hill target net positive nature reducing facility new york environmental impacts across water materials biodiversity member ev committed transition sales fleet investing protecting restoring nature lowcarbon vehicles install charging infrastructure sites involved developing standardised guidance measuring nature sales fleet electric hybrid vehicles vehicle positive working science based targets nature sbtn chargers sites weve set pilot project us partnership initiative partnering un environment programme world fleet management company deploy electric hybrid plugin conservation monitoring centre unepwcmc test sbtn methodology vehicles install home chargers provide seamless experience map impact nature across value chain people also members taskforce naturerelated financial disclosures gskcom renewable energy investments carbon pathway net zero tnfd working develop deliver risk management financial disclosure framework see esg reporting criteria pages definition gsk esg performance report march environment continued water reduced waste sites recovered materials circular routes like reuse recycling water targets achieve good water stewardship sites consumer healthcare launched million recycleready toothpaste tubes markets part ambition make one billion reduce overall water use operations toothpaste tubes recyclable significant milestone towards water neutral operations key suppliers water consumer healthcares ambition developed solutions stressed regions packaging recycleready zero impact active pharmaceutical ingredient levels sites key part ecodesign programme developed tools help suppliers scientists engineers reduce environmental impact future products reduced overall water use operations compared development stage sites high water stress regions sites building waste footprint identify hotspots across supply chain good water stewards line alliance water stewardships definition use footprint engage suppliers waste reductions also run waterefficiency projects sites including behaviour change help us find opportunities reduce products end life waste programmes introducing waterefficient cleaning procedures gsk sites biodiversity complete water stewardship assessment delivering action plans comply standard targets joined water resilience coalition partnering positive impact biodiversity sites develop approach water neutrality waterstressed regions materials sustainably sourced deforestation free deliver water resilience projects ground achieve net positive biodiversity sites outweigh impact weve identified eight initial water basins water stressed regions local ecosystems improving habitats protecting species manufacturing sites including south africa india pakistan improving soil water quality making nature easily accessible sites cape town site south africa first gsk network embark also positive impact health wellbeing people wider journey towards water neutrality site reduced water municipal community supply since working water resilience coalition local partners address shared water challenges clearing alien plant piloted approach biodiversity baseline assessment species replanting local flora create greater resilience basin action plans three sites sites biodiversity action plans gskcom water footprint stevenage site uk established baseline species habitats site weve created landscape plan partnership kew committed keeping active pharmaceutical ingredient api gardens deliver increase biodiversity site including grass emissions manufacturing including might contribute wood heathlands working natural england calculate antimicrobial resistance amr levels negative impact additional benefits water air quality human health pilot project human health environment rolled ensuring gsk sites measurable effective sites suppliers manufacture antibiotics biodiversity plans place complied amr alliance industry standards safe discharges gskcom biodiversity gsk sites partner innovative medicines initiative project focused prioritisation risk evaluation medicines environment premier sustainable sourcing involves working stakeholders agree safe levels environmental target risk apis making environmental data apis accessible agricultural forestry marine derived materials sustainably supporting greener design manufacturing pharmaceuticals sourced deforestation free gskcom pharmaceuticals environment developed sustainable sourcing plans highestrisk materials circular economy materials supply chain including paper palm oil soy going changed scope waste targets support transition beyond first tier suppliers map materials sourced circular economy keeps materials resources use putting place action plans increase sustainability targets zero operational waste including eliminating singleuse plastics environmental impact reduction products packaging waste reduction supply chain see esg reporting criteria pages definition measure waste generated includes waste recover dispose onsite enables us report circularity gsk esg performance report march environment continued membership action sustainable derivatives helped us trace carbon trust certified trelegy ellipta uk first carbon palm oil volume back mill level paper packaging tier supply neutral medicine weve achieved starting deliver product chains certified forest stewardship council programme specific carbon reduction plan offsetting remaining carbon endorsement forest certification currently reduced supporting reforestation project ghana ambition move synthetic sustainable alternatives animal protecting forests fundamental fighting climate change biodiversity loss based materials take time ensure efficacy safety safeguarding health cleaning water air joined products compromised secure regulatory approval publicprivate lowering emissions accelerating forest finance leaf coalition contributes highquality emissions reductions supporting naturebased solutions countries protect tropical forests deforestation leaf mobilised exploring naturebased solutions offset impacts cant billion financing one largest ever publicprivate efforts help eliminate address climate change restore nature create health benefits protect tropical forests gsk agree first projects support notes energy gwh natural gas purchased electricity used purchased renewable electricity assured dnv purchased nonrenewable electricity onsite generated renewable electricity exported electricity coal fossil fuels renewable heat purchased heating cooling renewable electricity total energy operations assured dnv carbon scope emissions onsite fuel use thousands tonnes co e sales force vehicles thousands tonnes co e propellant emissions manufacture inhalers thousands tonnes co e onsite waste wastewater treatment thousands tonnes co e refrigerant gas losses thousands tonnes co e total scope emissions thousands tonnes co e assured dnv electricity marketbased emissions thousands tonnes co e purchased heating cooling thousands tonnes co e total scope emissions marketbased thousands tonnes co e assured dnv scope locationbased emissions thousand tonnes coe assured dnv total scope emissions marketbased thousands tonnes co e assured dnv fermentationbiogenic releases thousands tonnes co e gsk esg performance report march environment continued notes carbon scope emissions purchased goods services thousands tonnes co e capital goods thousands tonnes co e fuel energyrelated activities thousands tonnes co e transportation distribution upstream thousands tonnes co e waste generated operations thousands tonnes co e business travel thousands tonnes co e employee commuting thousands tonnes co e leased assets upstream thousands tonnes co e transportation distribution downstream thousands tonnes co e processing sold products thousands tonnes co e use sold products thousands tonnes co e e missions use propellantbased inhalers patients assured dnv thousands tonnes coe end life thousands tonnes co e leased assets downstream thousands tonnes co e franchises thousands tonnes co e investments thousands tonnes co e total scope emissions thousands tonnes co e ozone depleting substances odp inventory cfc hcfc equipment kg cfce odp calculated releases cfc equiv kg cfce water use municipal million ground water million tankers million total water use million assured dnv recycled sources million water use high water risk sites million assured dnv water discharge wastewater municipal sewer million wastewater surface water million wastewater million wastewater discharged land million total wastewater discharged million assured dnv propellant emissions data collected internal systems accurate picture scope ghg emissions later year e missions classified downstream transportation previous years reclassified upstream transportation emissions advice carbon trust r eduction caused impact pandemic ee gsks high water risk sites gsk esg performance report march environment continued notes waste total waste generated thousand tonnes assured dnv total waste recovered circular route thousand tonnes assured dnv circular waste assured dnv total hazardous waste thousand tonnes total hazardous waste recovered circular route thousand tonnes total nonhazardous waste thousand tonnes total nonhazardous waste recovered circular route thousand tonnes total waste landfill thousand tonnes assured dnv compliance ehs internal audits gsk sites facilities ehs ethics labour rights audits rd party suppliers environmental fines environmental remediation spend million gsks definition total waste generated updated see kpi definitions take responsibility removing pollution contaminants soil surface ground water facilities used previously disposal sites waste management companies used gsk esg performance report march gri guidelines sasb index grisasb find indicator description information gri guidelines general disclosures name organization glaxosmithkline plc activities brands products services annual report location headquarters brentford middlesex tw gs uk location operations brentford middlesex tw gs uk ownership legal form annual report markets served annual report scale organisation annual report information employees workers supply chain significant changes organisation supply chain precautionary principle approach annual report externally developed economic environmental social charters principles initiatives annual report organization subscribes endorses membership associations trade association membership statement senior decisionmaker annual report values principlesstandards norms behaviour governance structure organization including committees highest governance body responsible responsibility decision making economic environmental social topics list stakeholder groups annual report identifying selecting stakeholders materiality assessment approach stakeholder engagement annual report key topics concerns raised materiality assessment changes reporting significant changes reporting period jandec date recent report reporting cycle annual contact point questions regarding report csrcontactgskcom claims reporting accordance gri standards reporting archive gri content index resources external assurance specific standard disclosures economic economic performance materiality assessment generic disclosures management approach direct economic value generated distributed annual report indirect economic impacts materiality assessment generic disclosures management approach significant indirect economic impacts including extent impacts anticorruption materiality assessment generic disclosures management approach communications training anticorruption approach tax tax strategy tax governance control risk management tax strategy social occupational health safety generic disclosures management approach rates injury occupational diseases lost days absenteeism work related fatalities gsk esg performance report march gri guidelines sasb index continued grisasb find indicator description information training education generic disclosures management approach employees receiving regular performance career development reviews diversity generic disclosures management approach diversity governance bodies employees society marketing labelling materiality assessment generic disclosures management approach incidents noncompliance concerning product service information labelling operating responsibly human rights generic disclosures management approach environment energy consumption within organization reduction energy consumption reductions energy requirements products services water materiality assessment generic disclosure management approach water withdrawal water discharge climate change generic disclosure management approach direct scope ghg emissions energy indirect scope ghg emissions indirect scope ghg emissions annual report ghg emissions intensity annual report emissions ozonedepleting substances ods waste packaging generic disclosure management approach waste discharge quality destination waste type disposal method noncompliance environmental laws regulations ssaassbb iinnddeexx safety clinical trial participants hcbpa discussion world region management process ensuring quality patient safety clinical trials approach clinical trials hcbpa number fda sponsor inspections related clinical trial management pharmacovigilance resulted voluntary action indicated vai official action indicated oai hcbpa total amount monetary losses result legal proceedings associated clinical trials developing reported countries access medicines hcbpa description actions initiatives promote access health care products priority diseases priority countries defined access medicine index hcbpa list products list prequalified medicinal products part prequalification medicines programme pqp affordabilty pricing hcbpb number settlements abbreviated new drug application anda litigation involved payments andor reported provisions delay bringing authorized generic product market defined time period hcbpb percentage change average list price average net price across us product portfolio compared previous year hcbpb percentage change list price net price product largest increase compared previous year gsk esg performance report march gri guidelines sasb index continued grisasb find indicator description information drug safety hcbpa list products listed food drug administrations fda medwatch safety alerts human medical available via fda products database hcbpa number fatalities associated products reported fda adverse event reporting system available via fda hcbpa number fda recalls issued total units recalled hcbpa total amount product accepted takeback reuse disposal reported hcbpa number fda enforcement actions taken response violations current good manufacturing practices cgmp type counterfeit drugs hcbpa description methods technologies used maintain traceability products throughout supply chain falsified prevent counterfeiting substandard healthcare products hcbpa discussion process alerting customers business partners potential known risks associated counterfeit products hcbpa number actions led raids seizure arrests andor filing criminal charges related counterfeit reported products ethical marketing hcbpa total amount monetary losses result legal proceedings associated false marketing claims reported hcbpa description code ethics governing promotion offlabel use products marketing practices scientific engagement employee recruitment development retention hcbpa discussion talent recruitment retention efforts scientists research development personnel hcbpa voluntary involuntary turnover rate executivessenior managers b midlevel managers c professionals others supply chain management hcbpa percentage entitys facilities tier suppliers facilities participating rx international gsk member rx pharmaceutical supply chain consortium audit program equivalent thirdparty audit programs integrity also conducts supply chain ingredients audits third parties business ethics hcbpa total amount monetary losses result legal proceedings associated corruption bribery reported hcbpa description code ethics governing interactions health care professionals code practice activity metrics hcbpa number patients treated patients reached access strategies hcbpb number drugs portfolio research development phases annual report list products list prequalified medicinal products vaccines part prequalification medicines programme pqp type form presentation date prequalification vaccines engerix hepatitis b liquid ready use vial dose thursday january engerix hepatitis b liquid ready use vial doses thursday january engerix hepatitis b liquid ready use vial doses thursday january priorix measles mumps rubella lyophilised active component reconstituted excipient friday march diluent use vial dose rotarix rotavirus liquid ready use plastic tube dose thursday march rotarix rotavirus liquid ready use applicator dose thursday march gsk esg performance report march gri guidelines sasb index continued type form presentation date prequalification vaccines cervarix human papillomavirus bivalent liquid ready use vial dose wednesday july cervarix human papillomavirus bivalent liquid ready use vial dose wednesday july polio sabin mono polio vaccine oral opv monovalent type liquid ready use vial dose thursday october polio sabin mono polio vaccine oral opv monovalent type liquid ready use vial dose thursday october polio sabin one three polio vaccine oral opv bivalent types liquid ready use vial doses thursday october polio sabin one three polio vaccine oral opv bivalent types liquid ready use vial doses thursday october synflorix pneumococcal conjugate liquid ready use vial dose friday october synflorix pneumococcal conjugate liquid ready use vial doses friday march polio sabin mono three oral polio vaccine oral opv monovalent type liquid ready use vial doses tuesday october polio sabin mono three oral polio vaccine oral opv monovalent type liquid ready use vial doses tuesday october polio sabin mono two oral polio vaccine oral opv monovalent type liquid ready use vial doses wednesday may polio sabin mono two oral polio vaccine oral opv monovalent type liquid ready use vial doses wednesday may priorix measles mumps rubella lyophilised active component reconstituted excipient wednesday december diluent use vial doses havrix adult hepatitis human diploid cell inactivated adult liquid ready use vial dose friday july hepatitis human diploid cell inactivated paediatric liquid ready use vial havrix junior friday july dose boostrix diphtheriatetanuspertussis acellular liquid ready use vial dose tuesday july menveo meningococcal acyw conjugate vaccine lyophilised active component reconstituted wednesday july liquid active component use two vial set dose synflorix pneumococcal conjugate liquid ready use vial doses monday october rotarix rotavirus liquid ready use plastic tube dose thursday february type applicant ref number date prequalification pharmaceuticals abacavir sulfate hiv viiv healthcare ha march abacavir sulfate hiv viiv healthcare ha march zidovudine hiv viiv healthcare ha may zidovudine hiv viiv healthcare ha may lamivudinezidovudine hiv viiv healthcare ha march zidovudine hiv viiv healthcare ha march zidovudine hiv viiv healthcare ha march lamivudine hiv viiv healthcare ha march lamivudine hiv viiv healthcare ha march dolutegravir sodium hiv viiv healthcare ha october abacavir sulfatelamivudine hiv viiv healthcare ha june dolutegravir sodium hiv viiv healthcare ha july zanamivir influenza gsk september gsk esg performance report march un global compact communication progress statement support ceo gsk remains committed upholding ungcs ten principles human rights environment anticorruption aim embedding policies standards across business remaining true purpose emma walmsley chief executive officer march find information implementing principles strategies mainstreaming corporate place responsibility execution sustainability strategy relevant corporate governance structure functions business units functions procurement government affairs human resources legal etc ensuring function conflicts companys sustainability commitments objectives align strategies goals incentive structures business units subsidiaries longterm priorities apply three corporate sustainability strategy businesses assign responsibility corporate sustainability implementation individual governance structure group within business unit subsidiary describes value communicate policies expectations suppliers relevant business chain implementation partners implement monitoring assurance mechanisms eg audits screenings compliance within companys sphere influence undertake awarenessraising training types capacity building suppliers business partners robust human rights management policies procedures robust commitments strategies commitment comply applicable laws respect internationally recognised gsk human rights statement policies area human human rights wherever company operates rights integrated standalone statement policy expressing commitment respect gsk human rights statement support human rights approved senior level company statement policy publicly available communicated internally externally gsk human rights statement personnel business partners relevant parties describes effective management ongoing due diligence process includes assessment actual potential systems integrate human human rights impacts rights principles allocation responsibilities accountability addressing human rights impacts describes effective monitoring relevant policies procedures activities company plans undertake evaluation mechanisms fulfil criterion including goals timelines metrics responsible staff human rights integration system monitor effectiveness human rights policies implementation quantitative qualitative metrics including supply chain describes robust commitments reference principles relevant international labour standards gsk human rights statement strategies policies ilo conventions normative international instruments area labour company policies inclusion reference principles contained relevant international labour standards contracts suppliers relevant business partners describes effective management risk impact assessments area labour systems integrate labour practices grievance mechanisms communication channels procedures eg whistleblower mechanisms available workers report concerns make suggestions seek advice designed operated agreement representative organisation workers robust labour management policies procedures continued describes effective monitoring audits steps monitor improve working conditions companies evaluation mechanisms supply chain line principles international labour standards labour principles integration process positively engage suppliers address challenges schemes improve workplace practices gsk esg performance report march un global compact communication progress continued find information robust environmental management policies procedures describes robust commitments reflection relevance environmental stewardship company strategies policies area environmental stewardship written company policy environmental stewardship manage environmental risks inclusion minimum environmental standards contracts suppliers relevant business partners specific commitments goals specified years describes effective management environmental risk impact assessments annual report systems integrate environmental principles allocation responsibilities accountability within organisation governance structure describes effective monitoring system track measure performance based standardised performance evaluation mechanisms metrics environmental stewardship audits steps monitor improve environmental performance companies supply chain robust anticorruption management policies procedures describes robust commitments publicly stated formal policy zerotolerance corruption antibribery corruption policy strategies policies area policy anticorruption regarding business partners antibribery corruption policy anticorruption third party guidelines describes effective management support organisations leadership anticorruption systems internal checks balances ensure consistency anticorruption integrate anticorruption commitment principle management responsibility accountability implementation anticorruption commitment policy communications whistle blowing channels followup mechanisms reporting concerns seeking advice describes effective monitoring leadership review monitoring improvement results evaluation mechanisms integration anticorruption taking action support global goals describes core business align core business strategy one relevant un goalsissues sdg factsheet contributions un goals issues develop relevant products services design business models contribute un goalsissues describes strategic pursue social investments philanthropic contributions tie core social investments competencies operating context company integrated part philanthropy sustainability strategy describes advocacy publicly advocate importance action relation one un goalsissues sdg factsheet public policy engagement gsk human rights statement commit company leaders participate key summits conferences sdg factsheet important public policy interactions relation one un goalsissues gsk human rights statement taking action support global goals continued describes partnerships develop implement partnership projects public private organisations collective action core business social investments andor advocacy join industry peers un entities andor stakeholders initiatives contributing solving common challenges dilemmas global andor local levels emphasis initiatives extending companys positive impact value chain gsk esg performance report march un global compact communication progress continued find information corporate sustainability governance leadership describes ceo commitment ceo publicly delivers explicit statements demonstrates personal leadership ungc cop ceo statement leadership sustainability commitment un global compact ceo promotes initiatives enhance sustainability companys sector leads ceos statement development industry standards describes board adoption board directors equivalent assumes responsibility oversight longterm cr committee report oversight corporate sustainability strategy performance ceos statement board establishes permissible committee assigns individual board cr committee report member responsibility corporate sustainability board committee permissible approves formal reporting corporate cr committee report sustainability communication progress governance describes stakeholder publicly recognises responsibility companys impacts internal external annual report engagement stakeholders define sustainability strategies goals policies consultation key annual report stakeholders establish channels engage employees stakeholders hear ideas address concerns protect whistle blowers gsk esg performance report march esg reporting criteria kpi definition method social governance data unless stated otherwise data reflects reporting period january december access affordability community investment donations made gsk globally charitable donations included voluntary charitable purpose totals million purposes including cash product inkind donations donations valued sterling year end exchange rates value time donated via pulse employee volunteering programme management costs product donations valued global average cost goods reported yearend associated charitable programmes results inkind donations valued value cost item gsk current external purchase price previous years data included comparison restated inflation exchange rate changes methodology used follows bsi formerly lbg framework corporate community investment albendazole tablets number albendazole tablets donated albendazole tablet shipments sent gsks manufacturing facility endemic donated help world health organization support endemic countries shipments entered realtime database donated medicines eliminate lymphatic country efforts eliminate lymphatic filariasis lf neglected tropical diseases albendazole tablet donation figures lf aggregated filariasis millions reported annually data pulled system albendazole tablets number albendazole tablets donated albendazole tablet shipments sent gsks manufacturing facility endemic donated help treat world health organization support endemic countries shipments entered realtime database donated medicines intestinal worms country efforts treat soiltransmitted helminthiasis neglected tropical diseases albendazole tablet donation figures soiltransmitted millions intestinal worms schoolage children helminthiasis control aggregated reported annually data pulled system value gsk medicine value medicine vaccines provided gsk viiv patient assistance programs foundation administers patient vaccines gsk viiv healthcare patient assistance assistance programs patients us puerto rico us virgin islands prescribed programs foundation provides medication capture patient assistance program orders gsk viiv healthcare products us patient assistance charge eligible individuals internal database data captured according wholesale acquisition program cogs patients receive medications cost medicine vaccine coded free good charitable orders million usd patient assistance programs must meet eligibility amount converted cost goods sold amount reporting purposes requirements requirements include insurance patient participation varies annually based current program eligibility criteria status financial component based federal products included programs poverty level resident us puerto rico us virgin islands treated uslicensed healthcare provider product reach target people access total number people living hiv currently chronic ongoing treatment capture cumulative number people generic dolutegravir accessing generic dolutegravirbased products access dolutegravir rather annual data avoid duplication indicator therefore product viiv healthcares voluntary license represents total number people living hiv accessing treatment time voluntary licensing agreements medicines patent pool measurement lifelong treatment number incorporates people agreements directly aurobindo pharma receiving ongoing treatment multiple years number calculated quarter taking average total number dolutegravir packs sold per quarter across last four quarters divided three obtain average monthly sales estimate number people treatment packs converted pack equivalents ie monthly equivalents daily treatment sales dolutegravir mg singles excluded data provided based cumulative figures end q data provided medicines patent pool aurobindo viivs dtg patents sublicensed estimated children estimated number children received calculate estimated number children reached use number gsk doses reached synflorix synflorix vaccine prevention shipped gavi divide number doses needed complete full gavi pneumococcal infection gavi global schedule gavi estimated vaccine wastage rates factored synflorix full vaccine alliance bringing together public private schedule three doses gavi estimates wastage sectors see detailedproductprofilesxlsx livecom children receiving synflorix five years age estimated children estimated number children received calculate estimated number children reached use number gsk doses reached rotarix rotarix vaccine prevention rotavirus shipped gavi divide number doses needed complete full gavi gavi global vaccine alliance bringing schedule gavi estimated vaccine wastage rates factored rotarix full together public private sectors schedule two doses gavi estimates wastage see detailedproductprofilesxlsx livecom children receiving rotarix five years age gsk esg performance report march esg reporting criteria continued kpi definition method estimated girls reached estimated number girls received calculate estimated number girls reached use number gsk doses cervarix cervarix vaccine prevention cervical shipped gavi divide number doses needed complete full schedule gavi cancer gavi global vaccine alliance gavi estimated vaccine wastage rates factored cervarix full schedule two bringing together public private sectors doses gavi estimates wastage see detailedproductprofilesxlsx livecom estimated people estimated number people received calculate estimated number people reached use number bivalent opv reached oral opv vaccine polio unicef bopv monovalent opv mopv doses shipped unicef divided number polio vaccine opv doses needed complete full schedule estimated vaccine wastage rates factored outbreak situations gsk opv volumes often used one dose usually given child however primary schedule four doses children may receive one dose subsequent outbreak campaigns use four doses calculation order conservative estimates wastage given supply dose vials may may used discarded end session vial opened see indicative vaccine wastage rates revisingwastageconceptnotepdf whoint people reached total number unique individuals received gsk viiv patient assistance programs foundation administers patient us patient gsk viiv healthcare product assistance programs patients us puerto rico us virgin islands assistance program patient assistance programs us patient assistance programs provides report yearend enables patients receive medications patient us consolidate number unique patients received gsk viiv healthcare assistance programs must meet eligibility products throughout year requirements requirements include insurance patient participation varies annually based current program eligibility criteria products status financial component based federal included programs poverty level resident us puerto rico us virgin islands treated uslicensed healthcare provider health access target people accessing total number people directly reached figure calculated combining reach gskfunded save children healthcare service save childrens gskfunded activities disease programmes operate lowincome countries focus building world worker educational prevention access health services child age five dies preventable causes information session programmes found website work save figure includes children adults directly reached healthcare example children immunisation programmes screening malnutrition treated pneumonia malaria diarrhoea well community members civil society members health workers trained directly engaged figure include indirectly reached includes people reached indirectly communications information education communication programmes campaigning andor awareness raising efforts events conducted supported save children one implementing partners reach data collected provided save children data covers period july june latest available data h data added h data proxy total data final data available april report updated reflect actual figure people accessing total number people directly reached gates ceo roundtable programme trains community health workers six countries healthcare worker community healthcare workers trained liberia uganda kenya ethiopia sierra leone malawi aim improving access service facility programme primary health care underserved communities funded five pharmaceutical result gates companies gsk jj novartis lilly pfizer bill melinda gates foundation ceo roundtable reach data collected provided ngo partners funder programme organizations equal contributor reach number calculated dividing total reach programme six data covers period july june latest available data h data added h data proxy total data final data available april report updated reflect actual figure people reached total number people directly reached viiv december positive action launched strategy grants made viiv healthcares healthcares positive action strategy communitybased organisations achieve healthy communities world free aids positive action grants reach data collected provided grantees data capture strategy grants month cycle grantees report every sixmonths previous sixmonths therefore grantees continue report data june grantee reporting began october limited data used proxy data final data available june report updated reflect actual figure gsk esg performance report march esg reporting criteria continued kpi definition method people employee survey engagement score index expressed survey issued regular fulltime fixed term contract employees engagement score percentage score derived responses countries gsk operates except china strongly agreed agreed four engagement engagement score calculated four questions comprising feeling valued questions gsk annual engagement survey proud employee opportunity challenging interesting work pharmaceutical vaccines employees recommending gsk great place work consumer health employees responded employee survey questions translated professional service partners survey consolidated response rate languages reviewed overseas nationals ensure translation quality accuracy due distinct nature businesses two separate surveys issued consumer health employees pharmaceutical vaccines employees engagement questions consistent surveys data consolidated report enterprisewide employee survey engagement score total women total percentage women management data covers total number salaried employees identify women within hr management role management classed employee system including active fulltimeparttime regulartemporary employees nonactive grade bands includes managers directors ie maternity leave paternity leave adoption leave etc excludes agency vps svps temporary workers contingent workers eg payrolled via recruitment agencies employees gender recorded indicated prefer say percentage calculated using employee numbers december calculated number salaried employees december recorded hr system gender specified female within grades divided total pay rolled employees recorded hr system number apprentices number employees joining gsk one new apprentices recruited globally tagged recorded hr system recruited formal apprenticeship early talent programmes exception apprentices recruited germany local hr team provides year manual data incorporated gsk total formal apprenticeship early talent programme defined structured programme individuals recruited school technical college gsk develop specific functional skills planned work experience addition associates programmes complete element formal education specified apprentice standard market employed supports targeted skills development overall turnover overall turnover measure gsk employees calculate number leavers year average permanent leaving gsk include internal moves headcount within site employee turnover rate includes employees left company voluntarily involuntarily year ethnically diverse total total percentage ethnically diverse employees data covers total number employees salaried internal hr system gsk us uk employee population across active including fulltimeparttime regulartemporary employees nonactive ie svpvp level director level manager level maternity leave paternity leave adoption leave etc excludes puerto ricobased across employees employees agency temporary workers contingent workers eg payrolled via recruitment agencies employees blank ethnicity prefer say us due differing ethnic groups across uk us figures exclude puerto ricobased employees given significant differences ethnic employee population raceethnic categories composition territorys population relative rest us defined according uk census us federal reporting guidelines percentage calculated using employee numbers december calculated number salaried employees december recorded internal hr system selfidentified ethnically diverse divided total salaried employees system ethical conduct compliance breakdown types policy violations data comprises regular employees excludes contractors contingent breakdown types employees disciplined year workers policy violation policy violations categories defined updated reporting methodology previous years reported concerns raised subsequent disciplinary actions reporting period behaviour workplace inappropriate data includes employees disciplined policy violations reporting year behaviourlanguage harassment discrimination cases closed expanded scope includes concerns raised previous employee inappropriate actions years employee disciplined expenses expense policy violations including individual employees subject multiple allegations resulting disciplinary action delinquent payment overspend local case individual counted unique category policy limits legitimate business expenditure improper unapproved expense fraudulent employee discipline results policy violation includes level sanction level expense claim sanction level sanction final warning termination resignation categorised appropriate outcomes employees including mediation demotion settlement good manufacturing distribution practices included counts percentages within categories outcome types violations good manufacturing practice considered disciplinary action represent situations employees supply chain continuity supply chain quality company work together towards solution assurance gsk esg performance report march esg reporting criteria continued kpi definition method ethical conduct compliance mandatory training completion late completion markets except germany utilise case management system manage cases breakdown types noncompletion mandatory training data retention german market maintains case list submitted policy violation worker global employee relations team year end consolidation analysis continued marketing promotional activities case owners regularly utilise published data quality reports assist data accuracy action behaviour language violation regularly quarterly internal audits conducted address outstanding data relating following antitrust discrepancies commercial practices funding contract sales organisation external experts healthcare professionalhospital class index transfer value inappropriate managerial direction interactions payer account groups consumerpayer groups product promotion samples speaker program policy violation types fit categories specified clinical trial transparency publicly available trial number clinical trial results summaries posted report cumulative number studies results disclosed since setup result summaries external facing gsk trial register www register gskstudyregistercom part gsks internal clinical results summaries must posted within one year completion studies policy commitment disclosure human subject due posted posted ahead time research addition mandatory requirements regulators disclosure research data number studies results summaries posted gsk summaries obtained gsk trial register wwwgskstudyregistercom advanced search feature gsk register studies results summaries selected search applied product quality audits third total number supplier audits carried gxp combined cumulative total across pharma vaccines consumer health business parties quality good practice quality guidelines regulations january december processes related activities including raw materials components based status number audits fieldwork completed within well good manufacturing practice services reporting period joint audits take place lead records audit external labs contract manufacturing organisations logistics service providers total regulatory total number good manufacturing practice combined cumulative total across pharma vaccines consumer health business inspections good distribution practice regulatory inspections january december global regulators based regulatory inspections fieldwork started product recalls number fda product number us fda recalls product us number recalls bu pharma vaccines consumer health businesses recalls business market categorise data according january december split class class businesses relates pharmaceutical vaccine business units track recalls respective systems data split class iiiiii consumer healthcare according recall type produce cumulative result class recall reasonable probability use exposure violative product cause serious adverse health consequences death class ii recall use exposure violative product may cause temporary medically reversible adverse health consequences probability serious adverse health consequences remote class iii recall use exposure violative product likely cause adverse health consequences number fda number gmp warning letters issued us number enforceable gmp warning letters bu pharma vaccines enforcement actions fda lead enforced regulatory actions consumer health business january december taken response required violations current good manufacturing practices cgmp gsk esg performance report march esg reporting criteria continued environmental data net zero emissions net zero emissions means reducing scope gsks carbon reduction plan available gskcom emissions much practicable line climate gsk aims offset around footprint using responsible highquality science maintain global temperature increases carbon removal solutions c balancing remaining residual emissions carbon removal credits net positive impact net nature positive means reducing approach delivery water waste biodiversity goals nature environmental impacts across water materials partnering organisations un water resilience coalition help us biodiversity investing measures protect positive water impact water stressed areas ellen macarthur foundation restore nature help us adopt circular approach waste materials un environment programme world conservation monitoring centre help us place biodiversity heart decision making aim source agricultural forestry marine derived materials sustainably member task force nature related financial disclosure tnfd water neutral water neutral means reasonable actions approach investing water efficiency projects sites taken reduce existing water footprint partnering un water resilience coalition ngos address shared water site aim balance impacts water use challenges community support sustainable use water within water basin water quality access within water basin rainwater harvesting projects capture water source reuse zero operational zero operational waste means routine waste approach reducing amount hazardous nonhazardous waste waste materials recovered circular routes see generated sites working eliminate noncircular methods waste definition waste disposal remainder reporting boundary published environmental data covers facilities gsk publish data aligned calendar year however december values include owned leased gsk joint venture estimates actual data available time publication data restated partners gsk full operational control correct december estimates reporting period except small commercial offices distribution baseline year environmental targets centres required report environmental impacts unless one following criteria met total energy usage mwh per annum total water per annum total waste generated tonnes per annum ensures gsk reporting environmental impacts energy includes purchased energy grid energy data based invoice data utility companies meter readings electricity natural gas coal diesel fuels renewably generated energy hot water solar wind biomass purchased renewable electricity renewable electricity generated supplier purchased supply agreement includes evidence origin rec regos part power purchase agreement ppa water includes water supplied gsk water data based invoice data suppliers meter readings sites captured rainwater recycled water measured reported included total water used calculation high water risk includes water supplied sites identified gsk mapped geographic location sites outputs tools gsk located region high water stress identify sites located regions highwater stress captured rainwater recycled water measured sites reported included total water used boudouaou algeria calculation cape town south africa region highwater stress defined gsk jamshoro pakistan region combined risk high karachi f pakistan high across three elements quantity quality wash water sanitisation hygiene karachi west wharf pakistan following tools wri aqueduct water risk atlas korangi pakistan wwf water risk filter nashik india nairobi kenya oak hill usa tianjin tskf china historic data restated cover sites also includes water supplied sites classed highwater stress sites left gsk network nabha india sonepat india tianyuan china world resources institute aqueduct water risk atlas last accessed th january wwf water risk filter last accessed th january gsk esg performance report march esg reporting criteria continued kpi definition method wastewater includes wastewater sent municipal wastewater data based invoice data utility companies meter readings sewer discharged surface water treatment calculation based water use absence meter site waste water used irrigation wastewater used recharge aquifers accordance local regulations liquid waste waste solvents contain water reported separately wastes scope carbon gsk scope emissions cover emissions carbon emissions calculated co equivalent coe per ghg protocol emissions direct combustion fuels sites generate corporate accounting reporting standard heat electricity emissions sales fleet carbon emission factors calorific factors combustion natural gas diesel vehicles fugitive losses propellant fuels taken uk government emission conversion factors greenhouse manufacturing inhalers losses gas company reporting edition emissions onsite solvent waste energy refrigerants used gsk owned ancillary equipment incineration historical data restated part emissions fuel instead emissions onsite waste treatment waste treatment emissions historical carbon emissions sales force travel calculated based distance travelled directly fuel use added estimate approx offices distance driven data available sales force emissions based fuel emissions distance vehicle data fleet providers carbon emissions refrigerant losses based quantities refrigerant used top equipment historical emissions refrigerant losses restated site waste treatment emissions based engineering estimates biogenic emissions reported separately included scope total emissions scope carbon gsk scope emissions include purchased carbon emissions calculated co equivalent coe per ghg protocol emissions electricity steam compressed air chilled water corporate accounting reporting standard carbon emission factors purchased electricity taken international energy agency statistics co fuel combustion edition carbon emission factors purchased heat steam chilled water taken uk government emission conversion factors greenhouse gas company reporting edition gsk restating scope emissions electricity based updated iea emission factors published gsk report marketbased scope emissions facilities evidence low carbon energy generation certificates origin rec rego ppa hydroelectric local grid supply eg quebec region scope carbon gsk report scope categories detailed carbon emissions calculated co equivalent coe per ghg protocol emissions greenhouse gas protocol corporate value chain scope standard scope data across categories prepared gsk using hybrid model combining primary activitybased data available economic data model quality assured carbon trust scope emissions business travel air based ticketing information directly fuel use scope emissions patient use metered dose inhalers based numbers inhalers leaving manufacturing sites distribution amount propellant inhaler waste revised definitions waste waste data based invoices waste transfer note data waste generated operational waste generated sites historical waste generated data waste generated leaves gsk boundaries waste recovered circular route includes waste materials generated site sent recyclingreclamation including offsite solvent recovery offsite reuse composting anaerobic digestion land treatment resulting benefit agriculture ecological improvement circular waste include solvent recovered recycled onsite gsk esg performance report march esg reporting criteria continued kpi definition method waste landfill waste landfill includes hazardous waste landfill data based invoices waste transfer note data nonhazardous waste disposed landfill cases local laws regulations require certain waste sent landfill types waste eg asbestos waste landfill best environmental option include wastes waste sent landfill data table also allow small number sites affected claim zero landfill status ozone depleting report ozone depleting potential total total amount ozone depleting substances based site inventory data multiplied substances contained amount ozone depleting substances contained ozone depleting potential factors intergovernmental panel climate equipment ancillary equipment kg cfc equivalents change estimate impact fugitive losses refrigerants excluding inventory small number sites gsk manage refrigeration equipment gsk reportable incident gsk reportable injury illness meets following consistent global reporting gsk reportable injury illness meets criteria listed criteria criteria different national regulatory reporting requirements vary across world affected individual either gsk employee worker direct gsk daily supervision lost time incident one resulted either days away work job transfer restriction employee unable perform one routine activities lost incident work related time days counted day following incident outcome involved least one hours worked calculated based number working days year length following average workday number employees site provided gsk human fatality resources employees include full time employees directly supervised agency staff loss consciousness medical treatment beyond first aid significant occupational injury occupational illness diagnosed physician licensed health care professional days away workrestricted daysjob transfer must new case gsk esg performance report march independent limited assurance report directors glaxosmithkline plc glaxosmithkline plc gsk commissioned dnv business assurance services uk limited dnv us conduct limited assurance engagement selected information presented esg performance report report reporting year ended december conclusion based procedures performed evidence obtained nothing come attention causes us believe selected informationisnotfairlystatedandhasnotbeenpreparedinallmaterialrespectsinaccordance withthecriteria conclusion relates selected information read context independent limitedassurancereportinparticulartheinherent limitations explained overleaf observations areas improvement raised separate report gsks management selected observations provided observations affect conclusion set identified gaps sitelevel reported distances used salesforce emissions calculation approach retrospectively updated retrieve coe emissions directly fleet suppliers recommend gsk develop documented methodology reporting salesforceemissionstosupportreplicabilityperiodicchecksofreported coeemissionsfromfleetsuppliers wouldimprovecontrolsaround thecompletenessofdata duringdatatestingwefoundgapsinthewastereportedforthreesitesuponinvestigationthecentralreportingteamconfirmedthisdatawas missingandupdatedthefigurespriortoreportpublicationwerecommendthecentralreportingteaminvestigatezerovaluesandanomalies atsitestomitigatetheriskofunderreportingdata ehsonehighlightsfiguresreportedofthepreviousmonth'svaluealthoughthiscoverserrorsfromincorrectconversionsoruomthe percentage gsks wider materiality threshold risk significant variations captured current system controlwerecommendthatgsksetsasystemwarningtoprovidecommentaryatgskswidermaterialitythreshold found gsk relies third parties provide data people reached gsks health target without established definitionandmethodologytoensurethatpeoplereachedarecountedconsistentlyacrossprogrammeswerecommendthatgskestablisha definition andmethodologyatgloballevelthatpartnerngosadheretoforreporting purposes toensureconsistentdataiscollectedacross gsk found data owners data collation calculation processes fully documented risk data reported consistently yearonyear may possible report data cases data owner unavailable recommendthatgskestablishasystematicprocessformaintainingandupdatingthedatamethodologyinternallytoimprovetheconsistency andefficiencyofreporting selectedinformation scope boundary work restricted environmental social competence independence governance esg performance data included within report selected quality control informationforthereportingyearandislistedinappendixofthisdocument toassesstheselectedinformationwhichincludesanassessmentoftheriskofmaterial misstatementinthereport wehaveusedgsksehstechnicalsupportdocumentsand dnv established policies procedures master internal data collection process criteria summary designedtoensurethatdnvitspersonneland foundonpagesofthereport applicable others subject independence requirements including performed work express conclusion personnel entities dnv information may published report gsks website current maintain independence required reportingperiodorforpreviousperiods relevant ethical requirements engagement work carried independent team sustainability assurance professionals multidisciplinary team consisted professionals combination environmental social sustainability assuranceexperience gsk esg performance report march standardandlevel ofassurance inherent limitations performed limited assurance engagement accordance international standard assurance engagements isae revised assurance engagements assurance engagements subject audits reviews historical financial information revised issued inherent limitations selective testing international auditing assurance standards board standard requires sampling may detect errors fraud comply ethical requirements plan perform assurance engagement irregularities nonfinancial data may obtainlimitedassurance subject greater inherent uncertainty financial data given nature dnvappliesits ownmanagementstandardsandcompliance policies quality control methodsused forcalculating estimating accordance isoiec conformity assessment requirements bodies determining data selection providing audit certification management systems accordingly maintains different acceptable measurement comprehensive system quality control including documented policies procedures techniques may result different regardingcompliancewithethicalrequirementsprofessionalstandardsandapplicablelegal quantificationsbetweendifferententities andregulatoryrequirements assurance relies premise data information provided us gsk procedures performed limited assurance engagement vary nature timing provided good faith dnv fromandarelessinextentthanforareasonableassuranceengagementandthelevelof expressly disclaims liability co assuranceobtainedissubstantiallylowerthantheassurancethatwouldhavebeenobtained responsibilityforanydecisionapersonoran hadareasonableassuranceengagementbeenperformed weplanned andperformedour entity may make based assurance worktoobtaintheevidenceweconsideredsufficienttoprovideabasisforourconclusion statement sothattheriskofthisconclusionbeinginerrorisreducedbutnotreducedtoverylow basisofourconclusion responsibilities directors required plan perform work order consider risk material gsk dnv misstatementoftheselectedinformationourworkincludedbutwasnotrestrictedto assessingtheappropriatenessofthecriteriafortheselectedinformation conducting interviews gsks management obtain understanding key directors gsk sole responsibility processessystemsandcontrolsinplacetogenerateaggregateandreporttheselected information preparing presenting selected desktopreviewofevidenceofsiteleveldataandfollowingthisthroughtoconsolidated information accordance groupdata criteria remote site visits levice slovakia wavre belgium zebulon usa review designingimplementingandmaintaining processes systems preparing site level ehs data consolidated gsks central effective internal controls reporting team dnvwerefreetochoosethesites onthe basis ofmaterialityandtheir information data resulting contributiontogsksoveralldata preparation selected information performinglimitedsubstantivetestingonaselectivebasisoftheselectedinformationto thatisfreefrommaterialmisstatements checkthatdatahadbeenappropriatelymeasuredrecordedcollatedandreporteddue measuring reporting selected strict confidentiality constraints unable review sample source data information based established gsks hr system case undertook alternative testing criteriaand methods quality control governance interviews ensure reliance contents statements contained data withinthereportandthecriteria recalculating selected information using suitable conversion factors andor ourresponsibility toplanandperform establishedbygskscriteria work obtain limited assurance reviewinginformationprovidedbygsksthirdpartycontractors whether selected information reviewingthattheevidencemeasurementsandthescopeprovidedtousbygskforthe preparedinaccordancewiththecriteria selectedinformationispreparedinlinewiththecriteriaand report gsk form readingthereportandnarrativeaccompanyingtheselectedinformationwithinitwith independent limited assurance conclusion regardtothecriteria based work performed evidence obtained responsibleforthepreparationofthereport dnv business assurance dnv business assurance services uk limited dnvbusiness assuranceservicesuklimited ispartofdnvbusinessassurance aglobal londonuk provider certification verification march assessment training services helping customers build sustainable business performance wwwdnvcoukbetterassurance gsk esg performance report march appendix selected information total energy operations gwh albendazole tablets donated help treat intestinal worms millions purchased renewable electricity gwh value gsk medicine vaccines prescribed us site renewably generated electricity gwh patient assistance program cogs million usd total scope emissions thousands tonnes coe people access generic dolutegravir product voluntary licensing agreements total scope emissions marketbased thousands tonnes coe scope locationbased emissions thousand tonnes coe estimated children reached synflorixthrough gavi total scope emissions marketbased thousands tonnes estimated children reached rotarix gavi coe estimated girls reached cervarixthrough gavi emissions use propellant based inhalers patients estimated people reached oral polio vaccine thousands tonnes coe people reached us patient assistance program total water use million people accessing healthcare service worker educational session total wastewater discharged million work save children ' water use high water risk sites million people reached viivhealthcares positive action strategy grants total waste generated thousand tonnes total waste landfill thousand tonnes people accessing healthcare worker service facility result gates ceo roundtable programme total circular waste engagement employee survey engagement score number fatalities employees complementary workers gsk direct supervision gender diversity total women management fatalities contractors gsk direct supervision talent leadership development number apprentices recruited reportable injuries lost time number employee turnover overall turnover reportable illnesses lost time number ethnicity us uk ethnically diverse total lost time reportable injury rate per hours worked compliance breakdown types policy violation lost time reportable illness rate per hours worked clinical trial transparency data publicly available trial result reportable injuries without lost time number summaries reportable illnesses without lost time number quality inspections audits audits rd parties quality processes reportable injury rate per hours worked total regulatory inspections reportable illness rate per hours worked number fda product recalls business class iiiiii reportable injury illness rate per hours worked pharmaceuticals vaccines consumer healthcare hours worked million number fda enforcement actions taken response violations total community investment million current good manufacturing practices cgmp pharmaceuticals vaccines consumer healthcare albendazole tablets donated help eliminate lymphatic filariasis millions gsk esg performance report march